Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases (Q38090679)

28 August 2017

title

Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases (English)

1 reference

28 August 2017

1 reference

Claire Bonfils

1

1 reference

28 August 2017

Donald R Walkinshaw

2

1 reference

28 August 2017

Jeffrey M Besterman

3

1 reference

28 August 2017

Xiang-Jiao Yang

4

1 reference

28 August 2017

Zuomei Li

5

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

Expert Opinion on Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

volume

3

1 reference

28 August 2017

issue

9

1 reference

28 August 2017

page(s)

1041-1065

1 reference

Acetylation: a regulatory modification to rival phosphorylation?

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Substrate and functional diversity of lysine acetylation revealed by a proteomics survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Sirtuins in mammals: insights into their biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Discovery and development of SAHA as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Vorinostat in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Clinical and molecular responses in lung cancer patients receiving Romidepsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Deacetylase inhibition promotes the generation and function of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Novel method for selecting immunosuppressive histone deacetylase (HDAC) inhibitors with minimal thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Mechanisms of HDAC inhibitor-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Treatment of spinal muscular atrophy by sodium butyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Recovery of learning and memory is associated with chromatin remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce gamma gene expression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Inhibition of histone deacetylation: a strategy for tumor radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.1041

Biological Activities in Animal Models.

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.56.80

10.1517/17460441.3.9.1041

12 April 2024

Identifiers

DOI

1 reference

28 August 2017

1 reference